drugset

drugset / Trial / NCT00190424

Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

NCT00190424 ↗

Phase 2 Completed 80 enrolled Assistance Publique - Hôpitaux de Paris

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma

Timeline

Start: 2005-09
Primary completion: 2008-10
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GNKG168	Oligonucleotide (other)	—	—

Indications